United Therapeutics reported $832.5 million in revenue for the quarter ended September 30, 2026, versus $799.5 million, while net income declined to $258.6 million from $338.7 million.
UTHR · UNITED THERAPEUTICS Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
United Therapeutics said Liquidia must remove PH-ILD from Yutrepia’s label after an adverse patent ruling and agreed to pay $330.4 million for past and future damages; Nebulized Tyvaso’s IPF application has an FDA goal date of April 26, 2027.
On October 21, 2026, United Therapeutics Corporation’s Board authorized repurchases of up to $2.0 billion of common stock through October 21, 2027; the company announced the program on October 22, 2026.
United Therapeutics and Liquidia settled patent litigation on October 13, 2026; Liquidia will pay $330.4 million, while United Therapeutics will pay $10.0 million to settle the RareGen/Sandoz litigation. Liquidia must remove PH-ILD from Yutrepia labeling and cease related marketing.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Second-quarter revenue declined 2% year over year to $783.3 million, below expectations, while net income rose 8% to $333.0 million. The company expects a stronger second half but did not reaffirm or update its 2026 revenue-growth outlook, while potential 2027 approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH remain important growth catalysts.
- + Net income increased 8% year over year to $333.0 million.
- + Tyvaso DPI exited the quarter with record starts, referrals, commercial patients, and total patients.
- + The company expects the second half of 2026 to be stronger than the first half.
- + Potential 2027 approvals are expected for Nebulized Tyvaso in IPF and ralinepag tablets in PAH.
- − Second-quarter revenue declined 2% year over year to $783.3 million and was below expectations.
- − The company did not reaffirm or update its 2026 revenue-growth expectations.
- − The path to the previously projected $4 billion revenue run rate by the end of 2027 has narrowed.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adcirca net product sales | $4.5M | FY2026 Q3 | -53.6% |
|
|
|||
| Nebulized Tyvaso net product sales | $122M | FY2026 Q3 | -3.1% |
|
|
|||
| Orenitram net product sales | $145M | FY2026 Q3 | +10.6% |
|
|
|||
| Remodulin net product sales | $122M | FY2026 Q3 | -3.1% |
|
|
|||
| Total Tyvaso revenues | $503.8M | FY2026 Q3 | +5.4% |
|
|
|||
| Tyvaso DPI net product sales | $378.5M | FY2026 Q3 | +12.6% |
|
|
|||
| Unituxin net product sales | $52.3M | FY2026 Q3 | +9.2% |
|
|
|||
| Remaining availability under share repurchase program | $500M | As of June 30, 2026 | — |
| Shares repurchased under the 2026 ASR agreements | 2,759,343 | In total | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
UTHR
this stock
UNITED THERAPEUTICS Corp
|
$25.18B | +21.3% | +2.4% | 22.3 | 4.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 23
United Therapeutics reported $832.5 million in revenue for the quarter ended September 30, 2026, versus $799.5 million, while net income declined to $258.6 million from $338.7 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| UTHR | +5.2% | +10.9% | +2.2% | -1.3% | +21.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +2.6% | +12.1% | +1.7% | -1.1% | +10.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.